Recent studies have revealed that DNA damage response inhibitors (DDRI), such as poly ADP-ribose polymerase inhibitors (PARPI), can enhance anti-tumor immunity by activating the cGAS-STING pathway [47]. This evidence concerns the gene STING1 and neoplasm.